Miniatura

Fitxers

European J of Heart Fail - 2022 - Butler - Health status improvement with ferric carboxymaltose in heart failure with.pdf (4.98 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-03-13

Llicència de publicació

cc by-nc-nd (c) Butler, Javed et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/187817

Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/ejhf.2478

Resum

Aim Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Methods and results Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least-square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of >= 5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), >= 10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or >= 15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a >= 5-, >= 10- or >= 15-point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24. Conclusion Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.

Matèries

Insuficiència cardíaca, Dèficit de ferro, Ús terapèutic

Matèries (anglès)

Heart failure, Iron deficiency diseases, Therapeutic use

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BUTLER, Javed, KHAN, Muhammad shahzeb, FRIEDE, Tim, JANKOWSKA, Ewa a., FABIEN, Vincent, GOEHRING, Udo michael, DORIGOTTI, Fabio, METRA, Marco, PIÑA, Ileana l., COATS, Andrew j. s., ROSANO, Giuseppe, COMÍN COLET, Josep, VAN VELDHUISEN, Dirk j., FILIPPATOS, Gerasimos s., ANKER, Stefan d., PONIKOWSKI, Piotr. Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency. _European Journal of Heart Failure_. 2022. Vol. 24, núm. 5, pàgs. 821-832. [consulta: 31 de gener de 2026]. ISSN: 1879-0844. [Disponible a: https://hdl.handle.net/2445/187817]

Exportar metadades

JSON - METS

Compartir registre